anti-VEGFR-2 immunoliposomes

Anti-VEGFR-2 immunoliposomes (anti-VEGFR2-ILs) are an experimental, targeted drug delivery system designed to selectively ablate tumor-associated endothelial cells and disrupt tumor vasculature. The system consists of anti-VEGFR-2 antibody fragments (such as Fab' fragments of the monoclonal antibody DC101) covalently conjugated to the lipid bilayer membrane of pegylated liposomal doxorubicin (PLD). By targeting vascular endothelial growth factor receptor-2 (VEGFR-2), which is selectively upregulated on tumor-associated endothelial cells during angiogenesis, the immunoliposomes deliver the cytotoxic payload doxorubicin directly to the tumor vasculature. This targeted delivery minimizes systemic toxicity while inhibiting tumor growth and angiogenesis. Preclinical studies, primarily conducted by academic researchers at the University of Basel, have demonstrated therapeutic efficacy in animal models of insulinoma, breast cancer, colon cancer, and hepatocellular carcinoma.

Other names

DC101-ILDC-101-ILDC 101-ILDC101-IL-doxDC-101-IL-doxDC 101-IL-doxanti-VEGFR-2 immunoliposomeanti-VEGFR2 immunoliposomeanti-VEGFR 2 immunoliposomeanti-VEGFR-2 immunoliposomesanti-VEGFR2 immunoliposomesanti-VEGFR 2 immunoliposomesanti-VEGFR2-ILsanti-VEGFR-2-ILsanti-VEGFR 2-ILsanti-VEGFR2-ILs-doxanti-VEGFR-2-ILs-doxanti-VEGFR 2-ILs-doxdoxorubicin-loaded anti-VEGFR2 immunoliposomes